Hepatitis B virus cccDNA

乙型肝炎病毒cccDNA

基本信息

  • 批准号:
    9764249
  • 负责人:
  • 金额:
    $ 45.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-15 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Hepatitis B virus chronically infects approximately 300 million people worldwide. All are at significantly increased risk of developing hepatocellular carcinoma. Although virus replication can be blocked by therapy with nucleoside analogs, infected hepatocytes are not cured, because covalently closed circular DNA (cccDNA), the template for transcription of viral RNAs persists in infected cells. So far, therapeutic strategies to prevent cccDNA formation or functionally inactivate or even destroy cccDNA within infected hepatocytes are lacking. The purpose of this application is to investigate four problems pertinent to cccDNA biology: identification of the enzymes required for cccDNA formation, elucidation of the exact mechanism for cccDNA formation, investigating how cccDNA is distributed to daughter cells during regeneration of hepatocytes and determining the physical organization of cccDNA in infected hepatocytes. Research on the mechanism of cccDNA formation could reveal the identity of cellular DNA repair enzymes that in turn, could be become targets for novel antiviral therapies. Investigations on the physical location of cccDNA in nuclei of infected cells could shed light on how cccDNA is maintained and distributed to daughter cells following cell division, and how it is eventually lost during spontaneous recovery from natural HBV infections. A better understanding of these processes is deemed essential for the development of novel strategies to cure chronic hepatitis B (CHB). Aim 1. Mechanism for cccDNA synthesis. We will identify still elusive cellular enzymes responsible for the conversion of rc to cccDNA. Candidates are DNA ligase(s) and endonuclease(s), required for the processing and joining of the 5’ and 3’ ends of the two rcDNA strands. Gene knockout cells will be used to determine how rcDNA is converted into cccDNA. In addition, we propose the development of a novel screening assay for identification of host genes required for HBV infection and cccDNA formation. Aim 2. cccDNA fate during cell division and nuclear localization. This aim builds on our ability to visualize cccDNA in metaphase and interphase nuclei by fluorescence in situ hybridization (FISH). The goal is to determine the distribution of cccDNA in DHBV and HBV producing cells and investigate how cccDNA is distributed to daughter cells under normal conditions and in the presence of cytokines. Experiments are designed to investigate the nuclear localization of functional and transcriptionally silenced cccDNA. To address these aims, we will rely on an experimental approach that builds on our research efforts during the past two years leading to cell culture platforms permitting HBV infections of HepG2 cells in combination with CRISPR/Cas9 gene knockout technology. In addition, the aims build on our recent success in developing methods permitting detection of cccDNA by FISH.
项目概要 乙型肝炎病毒长期感染全球约 3 亿人。全部都显着增加 发生肝细胞癌的风险。尽管核苷治疗可以阻止病毒复制 类似物,受感染的肝细胞无法治愈,因为共价闭合环状DNA(cccDNA)是 病毒RNA的转录在受感染的细胞中持续存在。迄今为止,预防cccDNA形成的治疗策略 或缺乏功能性失活甚至破坏受感染肝细胞内的 cccDNA。这样做的目的 该应用程序旨在研究与 cccDNA 生物学相关的四个问题: 鉴定所需的酶 cccDNA 形成,阐明 cccDNA 形成的确切机制,研究 cccDNA 是如何形成的 在肝细胞再生过程中分配给子细胞并确定其物理组织 受感染肝细胞中的 cccDNA。对cccDNA形成机制的研究可以揭示cccDNA的身份 细胞 DNA 修复酶反过来可能成为新型抗病毒疗法的靶标。调查 cccDNA 在受感染细胞核中的物理位置可以揭示 cccDNA 如何维持和 细胞分裂后分配给子细胞,以及它最终如何在自发恢复过程中丢失 来自天然 HBV 感染。更好地理解这些过程对于开发至关重要 治疗慢性乙型肝炎(CHB)的新策略。 目标 1. cccDNA 合成机制。我们将确定仍然难以捉摸的细胞酶,这些酶负责 rc 到 cccDNA 的转换。候选者是处理所需的 DNA 连接酶和核酸内切酶 以及连接两条 rcDNA 链的 5' 和 3' 端。基因敲除细胞将用于确定如何 rcDNA 转化为 cccDNA。此外,我们建议开发一种新的筛选方法 鉴定 HBV 感染和 cccDNA 形成所需的宿主基因。 目标 2. 细胞分裂和核定位过程中 cccDNA 的命运。这个目标建立在我们可视化的能力之上 通过荧光原位杂交 (FISH) 检测中期和间期细胞核中的 cccDNA。目标是 确定 cccDNA 在 DHBV 和 HBV 产生细胞中的分布并研究 cccDNA 的分布 在正常条件下和细胞因子存在的情况下分布到子细胞。实验设计 研究功能性和转录沉默 cccDNA 的核定位。 为了实现这些目标,我们将依靠基于我们的研究工作的实验方法 过去两年,细胞培养平台允许 HepG2 细胞与 HBV 感染相结合 CRISPR/Cas9基因敲除技术。此外,这些目标建立在我们最近成功开发 允许通过 FISH 检测 cccDNA 的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christoph Seeger其他文献

Christoph Seeger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christoph Seeger', 18)}}的其他基金

Hepatitis B virus cccDNA
乙型肝炎病毒cccDNA
  • 批准号:
    9973138
  • 财政年份:
    2018
  • 资助金额:
    $ 45.75万
  • 项目类别:
Hepatitis B virus cccDNA
乙型肝炎病毒cccDNA
  • 批准号:
    10214466
  • 财政年份:
    2018
  • 资助金额:
    $ 45.75万
  • 项目类别:
Designer Nucleases to Cure Chronic Hepatitis B
设计核酸酶可治愈慢性乙型肝炎
  • 批准号:
    8608995
  • 财政年份:
    2013
  • 资助金额:
    $ 45.75万
  • 项目类别:
Designer Nucleases to Cure Chronic Hepatitis B
设计核酸酶可治愈慢性乙型肝炎
  • 批准号:
    8424659
  • 财政年份:
    2013
  • 资助金额:
    $ 45.75万
  • 项目类别:
Mechanism of CCC DNA Synthesis in Hepatitis B Virus
乙型肝炎病毒CCC DNA合成机制
  • 批准号:
    8495929
  • 财政年份:
    2012
  • 资助金额:
    $ 45.75万
  • 项目类别:
Mechanism of CCC DNA Synthesis in Hepatitis B Virus
乙型肝炎病毒CCC DNA合成机制
  • 批准号:
    8355689
  • 财政年份:
    2012
  • 资助金额:
    $ 45.75万
  • 项目类别:
Inhibition of the Interferon Response by West Nile Virus
西尼罗河病毒对干扰素反应的抑制
  • 批准号:
    7491029
  • 财政年份:
    2007
  • 资助金额:
    $ 45.75万
  • 项目类别:
Inhibition of the Interferon Response by West Nile Virus
西尼罗河病毒对干扰素反应的抑制
  • 批准号:
    7676081
  • 财政年份:
    2007
  • 资助金额:
    $ 45.75万
  • 项目类别:
Inhibition of the Interferon Response by West Nile Virus
西尼罗河病毒对干扰素反应的抑制
  • 批准号:
    7919309
  • 财政年份:
    2007
  • 资助金额:
    $ 45.75万
  • 项目类别:
Inhibition of the Interferon Response by West Nile Virus
西尼罗河病毒对干扰素反应的抑制
  • 批准号:
    7322886
  • 财政年份:
    2007
  • 资助金额:
    $ 45.75万
  • 项目类别:

相似海外基金

Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
  • 批准号:
    10682185
  • 财政年份:
    2023
  • 资助金额:
    $ 45.75万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    475843
  • 财政年份:
    2022
  • 资助金额:
    $ 45.75万
  • 项目类别:
    Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    474485
  • 财政年份:
    2022
  • 资助金额:
    $ 45.75万
  • 项目类别:
    Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10683329
  • 财政年份:
    2022
  • 资助金额:
    $ 45.75万
  • 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10481430
  • 财政年份:
    2022
  • 资助金额:
    $ 45.75万
  • 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
  • 批准号:
    nhmrc : 1196520
  • 财政年份:
    2021
  • 资助金额:
    $ 45.75万
  • 项目类别:
    Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10260234
  • 财政年份:
    2021
  • 资助金额:
    $ 45.75万
  • 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10548114
  • 财政年份:
    2021
  • 资助金额:
    $ 45.75万
  • 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
  • 批准号:
    10400318
  • 财政年份:
    2020
  • 资助金额:
    $ 45.75万
  • 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
  • 批准号:
    20K08371
  • 财政年份:
    2020
  • 资助金额:
    $ 45.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了